Today, the FDA approved olaparib tablets (Lynparza) for the treatment of patients with metastatic breast cancer whose tumors have a germline genetic mutation, according to a press release. This was true at 2, 5 and 10 years following diagnosis. Most importantly, they uncovered that there was no difference in overall survival two, five, or ten years after diagnosis for women with and without a BRCA mutation.
'Women diagnosed with early breast cancer who carry a BRCA mutation are often offered double mastectomies soon after their diagnosis or chemotherapy treatment, however, our findings suggest that this surgery does not have to be immediately undertaken along with the other treatment.
"No other study has followed a group of patients from diagnosis over a long period of time to discover if carrying a high-risk inherited BRCA gene alters the likelihood of being cured of breast cancer", said lead researcher Professor Diana Eccles from the University of Southampton.
A study has found, however, that it has no effect on survival rates among young women.
Clovis' PARP inhibitor Rubraca (rucaparib) was approved in the U.S.in late 2016 for advanced ovarian cancer patients who have received at least two prior lines of chemo and whose tumors harbor the BRCA mutation.
A study of 1.8 million women demonstrated an increased risk of breast cancer with hormonal contraceptive use - including combined oral contraception (COC), progestin-only pills (POPs), and intrauterine systems - with a dose-response relationship. After 10 years, faulty gene carrier survival was 73.4% compared with 70.1% for non-carriers.
Angelina Jolie made headlines when she underwent preventative surgery after learning she had an up to 87% chance of developing breast cancer.
PALB2 - Works similarly to the BRCA genes.
Mutations in these genes stop DNA repairing itself and increase the risk of cancer developing.
The team tracked the women's medical records for an average period of just over eight years, and found that 651 of 678 total deaths were due to breast cancer. It means that they can take time to discuss whether radical breast surgery is the right choice for them as part of a longer-term risk-reducing strategy.
The study included 2733 women from 127 hospitals in the United Kingdom who had been diagnosed with breast cancer at the age of 40 or below.
'This study can reassure young women with breast cancer ... that breast conservation with radiotherapy is a safe option in the first decade after diagnosis and double mastectomy is not essential or mandatory at initial treatment.
'Decisions about timing of additional surgery to reduce future cancer risks should take into account patient prognosis after their first cancer, and their personal preferences'.
The researchers say that in the future this information could help women and their doctors make informed choices about treatment.